Samsung Biologics highlights faster drug manufacturing timelines at BPI Boston
Samsung Biologics showcased manufacturing technologies designed to accelerate biopharmaceutical development and improve product quality at BioProcess International (BPI) 2026 in Boston, highlighting efforts to streamline complex drug production. The company said Monday it participated in BPI from Sept. 22-25, drawing more than 3,000 biopharmaceutical professionals from around the world. Samsung…
Samsung Biologics highlighted its manufacturing technologies aimed at accelerating biopharmaceutical development and enhancing product quality at BioProcess International (BPI) 2026, held in Boston from September 22-25. The event drew over 3,000 biopharmaceutical professionals worldwide. Samsung Biologics, a consistent attendee of BPI for nine years, set up a booth demonstrating its capabilities, including contract research, development, manufacturing, and its unique Samsung Organoids technology for multiple modalities.
A presentation on Wednesday focused on the company's integrated chemistry, manufacturing, and controls strategy for bispecific and multispecific antibodies. According to the team, their molecule-specific process development reduced the timeline from 13 months to 9.5 months while preserving high-quality standards. Scientific posters were also presented during the conference.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
